Regulatory News
Wednesday, December 7, 2016
BRIEF-Abiomed's Impella CP receives expanded FDA approval for high-risk PCI procedures
* Abiomed Impella CP receives expanded FDA approval for
high-risk percutaneous coronary intervention (PCI) procedures
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment